Financial Performance - The company's operating revenue for Q1 2019 was ¥409,397,546.32, representing a 13.65% increase compared to ¥360,211,471.99 in the same period last year[3] - The net profit attributable to shareholders was ¥50,931,985.61, a decrease of 12.88% from ¥58,463,126.37 year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥40,683,222.82, down 27.41% from ¥56,041,854.52 in the previous year[3] - Basic earnings per share decreased to ¥0.0527, down 12.89% from ¥0.0605 year-on-year[3] - Total operating revenue for the current period reached ¥409,397,546.32, an increase of 13.6% compared to ¥360,211,471.99 in the previous period[24] - Net profit for the current period was ¥50,644,468.36, a decrease of 13.5% from ¥58,210,800.73 in the previous period[25] - Operating profit for the current period was ¥61,418,909.01, down 8.7% from ¥67,347,487.96 in the previous period[25] - The company reported a total comprehensive income of ¥87,921,660.43 for the current period, compared to ¥57,891,059.46 in the previous period, indicating a significant increase[29] - The total profit for the current period was ¥87,708,437.06, compared to ¥57,171,332.40 in the previous period, showing an increase of 53.3%[28] Cash Flow - The net cash flow from operating activities was negative at ¥63,776,462.86, a decline of 229.58% compared to ¥49,217,259.41 in the same period last year[3] - Cash inflow from operating activities was CNY 504,928,999.19, an increase from CNY 425,445,949.41 in the previous period, representing a growth of approximately 18.6%[31] - The net cash flow from operating activities was -CNY 63,776,462.86, compared to a positive cash flow of CNY 49,217,259.41 in the previous period[31] - Cash outflows for operating activities totaled CNY 568,705,462.05, up from CNY 376,228,690.00, indicating a significant increase of about 51%[31] - The cash inflow from investment activities was CNY 285,581,457.88, down from CNY 326,334,103.86, reflecting a decrease of approximately 12.5%[32] - The net cash flow from investment activities was -CNY 51,859,490.10, compared to -CNY 188,650,757.48 in the previous period, showing an improvement[32] - Cash inflow from financing activities was CNY 30,000,000.00, a decrease from CNY 86,665,377.01 in the previous period[32] - The net cash flow from financing activities was CNY 402,932.99, down from CNY 6,843,124.89, indicating a decline[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,915,441,089.40, a decrease of 1.36% from ¥5,997,069,913.93 at the end of the previous year[3] - The total liabilities decreased from CNY 1,249,313,522.82 to CNY 1,117,040,229.93, a reduction of approximately 10.55%[17] - The total owner's equity increased from CNY 4,747,756,391.11 to CNY 4,798,400,859.47, reflecting a growth of about 1.06%[18] - The company's current assets rose from CNY 891,819,841.71 to CNY 967,850,617.45, an increase of approximately 8.54%[20] - The non-current assets increased from CNY 3,766,797,515.22 to CNY 3,784,199,813.89, showing a growth of about 0.46%[20] - The total cash and cash equivalents at the end of the period were CNY 199,399,014.66, down from CNY 229,673,430.51[32] - The total liabilities to equity ratio improved from 1.63 to 1.47, indicating a stronger equity position[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,349[5] - The largest shareholder, Beijing Jinshang Alliance Investment Management Co., Ltd., held 45.97% of the shares, totaling 444,293,544 shares[5] - The net assets attributable to shareholders increased by 1.07% to ¥4,798,400,859.47 from ¥4,747,756,391.11 at the end of the previous year[3] Government Subsidies and Other Income - The company received government subsidies amounting to ¥12,318,144.41 during the reporting period[4] - Other income increased by 187.63% due to higher government subsidies received compared to the previous year[9] Research and Development - Research and development expenses increased to ¥3,685,405.11, compared to ¥3,206,428.27 in the previous period, reflecting a growth of 14.9%[24] Investment and Equity - Investment income decreased by 149.00% due to adjustments related to the equity method for newly acquired R&D institutions[9] - Long-term equity investments increased by 30.44% due to the acquisition of equity in Beida Shijia[9] - The company achieved an investment income of ¥97,770,934.63, up from ¥49,739,720.21 in the previous period, representing a growth of 96.5%[28] Operational Insights - The company is actively promoting a major asset restructuring to enhance profitability and improve shareholder returns[10] - The first quarter report of Tonghua Golden Horse Pharmaceutical Group Co., Ltd. is unaudited[42] - The report was released on April 26, 2019[42] - No specific financial performance metrics or user data were provided in the document[42] - Future outlook and performance guidance were not discussed in the report[42] - There were no mentions of new products or technology development in the document[42] - Market expansion and mergers or acquisitions were not addressed in the report[42] - Other new strategies were not outlined in the document[42] - The report does not include any financial figures or percentages[42] - The company did not provide any insights into operational performance or market trends[42] - The document lacks detailed analysis or commentary on the company's financial health[42]

通化金马药业集团股份有限公司 2018 年年度报告全文 通化金马药业集团股份有限公司 2018 年年度报告 2019 年 04 月 1 通化金马药业集团股份有限公司 2018 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人姬彦锋、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及公司未来发展展望、经营计划等前瞻性陈述，不构成对投 资者的实质承诺，请投资者认真阅读，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 通化金马药业集团股份有限公司 2018 年年度报告全文 目录 | --- | |--------------------------------------------| | | | 第一节 重要提示、目录和释义 | | 第二节 公司简介和主要财务指标. | | 第三节 公司业务概要 ... ... ...

通化金马药业集团股份有限公司 2018 年年度报告全文 通化金马药业集团股份有限公司 2018 年年度报告 2019 年 04 月 1 通化金马药业集团股份有限公司 2018 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人姬彦锋、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及公司未来发展展望、经营计划等前瞻性陈述，不构成对投 资者的实质承诺，请投资者认真阅读，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 通化金马药业集团股份有限公司 2018 年年度报告全文 目录 | --- | --- | |--------------------------------------------------------------------------------------------------------- ...

所有董事均已出席了审议本次季报的董事会会议。 公司负责人姬彦锋、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证季度报告中财务报表的真实、准确、完整。 通化金马药业集团股份有限公司 2018 年第三季度报告正文 证券代码：000766 证券简称：通化金马 公告编号：2018-148 通化金马药业集团股份有限公司 2018 年第三季度报告正文 1 通化金马药业集团股份有限公司 2018 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 2 通化金马药业集团股份有限公司 2018 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 6,062,117,736.17 | 5,726,837,493.11 | | 5.85% ...

通化金马药业集团股份有限公司 2018 年半年度报告全文 通化金马药业集团股份有限公司 1 通化金马药业集团股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人姬彦锋、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中所涉及的的未来计划、发展战略等前瞻性描述，不代表公司盈利 预测，不构成公司对投资者的实质承诺，投资者及相关人士均应对此保持足够 的风险认识，并且应当理解计划、预测与承诺之间的差异。请投资者注意投资 风险。 公司可能面临的风险详见本报告"第四节 经营情况讨论与分析"之"十、 公司面临的风险和应对措施"。 2018 年半年度报告 2018 年 08 月 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介和主要财务指标 ...

Financial Performance - The company's operating revenue for 2017 was CNY 1,521,410,294.36, representing a 78.97% increase compared to CNY 850,083,371.07 in 2016[18]. - The net profit attributable to shareholders for 2017 was CNY 257,879,255.54, a 20.81% increase from CNY 213,461,472.99 in 2016[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 245,507,558.17, up 22.67% from CNY 200,144,442.55 in 2016[18]. - Basic earnings per share for 2017 were CNY 0.27, an increase of 17.39% from CNY 0.23 in 2016[18]. - The company achieved a total revenue of ¥1,521,410,294.36, representing a year-on-year increase of 78.97%[35]. - Net profit attributable to shareholders reached ¥257,879,255.54, up 20.81% compared to the previous year[35]. - The company reported a total profit from continuing operations of CNY 257.09 million for the current year, compared to CNY 211.92 million in the previous year[99]. Cash Flow and Investments - The net cash flow from operating activities decreased by 70.83% to CNY 26,434,194.72 from CNY 90,629,099.82 in 2016[18]. - The company reported a significant decrease in net cash flow from investment activities, with a net outflow of ¥157,170,640.94, an improvement of 91.43% year-over-year[56]. - The total investment amount for the reporting period was ¥6,000,000, a drastic decrease of 99.29% compared to ¥842,100,000 in the previous year[59]. - Operating cash inflow increased by 53.82% to ¥1,448,192,837.49, while operating cash outflow rose by 67.10% to ¥1,421,758,642.77, resulting in a net cash flow from operating activities of ¥26,434,194.72, down 70.83%[56]. Assets and Liabilities - Total assets at the end of 2017 were CNY 5,726,837,493.11, a 7.98% increase from CNY 5,303,516,233.42 at the end of 2016[18]. - The net assets attributable to shareholders increased by 6.25% to CNY 4,380,799,206.14 from CNY 4,122,919,950.60 at the end of 2016[18]. - Short-term borrowings increased to ¥435,000,000.00, representing 7.60% of total liabilities, up from 2.83% the previous year[57]. - The total amount of purchases from the top five suppliers was ¥71,552,049.09, representing 26.47% of total annual purchases[49]. Research and Development - Research and development investment amounted to ¥60,392,074.85, representing a 43.25% increase from the previous year, but the R&D investment as a percentage of revenue decreased to 3.97%[52]. - The company is currently conducting Phase III clinical trials for a new drug, indicating ongoing investment in new product development[52]. - The company is focusing on new product development, including ongoing clinical trials for a new drug and several secondary development projects[38]. Market Strategy and Competition - The company focuses on product innovation and has shifted its marketing strategy towards professional academic marketing and precision marketing to enhance sales capabilities[29]. - The pharmaceutical manufacturing industry is experiencing increased competition and regulatory scrutiny, impacting pricing and profit margins for companies in the sector[29]. - The company is actively pursuing mergers and acquisitions, with two major asset restructuring initiatives launched during the reporting period[35]. Governance and Compliance - The company has established a commitment to avoid competition with its subsidiaries and ensure fair treatment of all shareholders[90]. - The independent directors have fulfilled their responsibilities effectively, contributing to the decision-making process regarding profit distribution[88]. - The company has committed to reducing and regulating related party transactions to avoid conflicts of interest[90]. Environmental and Social Responsibility - The company processed a total of 96,740 tons of wastewater in 2017, with a daily online monitoring and a water quality compliance rate of 100%[132]. - The company has actively engaged in social responsibility initiatives, including employment opportunities for local impoverished farmers and promoting suitable economic projects[128][129]. - The company received the "Outstanding Helping Enterprise" title from the Erdaojiang Poverty Alleviation Office in March 2018[129]. Future Outlook - The company plans to focus on strengthening governance, internal control, and performance management while controlling costs and making reasonable investments in 2018[76]. - The company aims to enhance its R&D and innovation capabilities, improve product structure, and expand its marketing network to increase market share in the domestic market[76]. - The company plans to enhance its R&D innovation system and increase investment in R&D, particularly focusing on key traditional Chinese medicine varieties[78].

通化金马药业集团股份有限公司 2018 年第一季度报告正文 证券代码：000766 证券简称：通化金马 公告编号：2018-57 通化金马药业集团股份有限公司 2018 年第一季度报告正文 1 通化金马药业集团股份有限公司 2018 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人姬彦锋、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证季度报告中财务报表的真实、准确、完整。 2 通化金马药业集团股份有限公司 2018 年第一季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 360,211,471.99 | 197,130,208.73 | 82.73% | | 归属于上市公司股东的净 ...

通化金马药业集团股份有限公司 2017 年年度报告全文 通化金马药业集团股份有限公司 2017 年年度报告 2018 年 04 月 1 通化金马药业集团股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人姬彦锋、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告涉及公司未来发展展望、经营计划等前瞻性陈述，不构成对投 资者的实质承诺，请投资者认真阅读，注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | | | | 第一节 重要提示、目录和释义 5 | | --- | | 第二节 公司简介和主要财务指标 9 | | 第三节 公司业务概要 11 | | 第四节 经营情况讨论与分析 25 | | 第五节 重要事项 43 | | 第六节 股份变动及股东情况 48 | | 第七节 优先股相关情况 48 | ...

通化金马药业集团股份有限公司 2017 年第三季度报告正文 1 证券代码：000766 证券简称：通化金马 公告编号：2017-102 通化金马药业集团股份有限公司 2017 年第三季度报告正文 通化金马药业集团股份有限公司 2017 年第三季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人姬彦锋、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证季度报告中财务报表的真实、准确、完整。 2 通化金马药业集团股份有限公司 2017 年第三季度报告正文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 5,547,679,271.67 | 5,303,516,233.42 | | 4.60% ...

通化金马药业集团股份有限公司 2017 年半年度报告全文 通化金马药业集团股份有限公司 2017 年半年度报告 2017 年 08 月 1 公司负责人姬彦锋、主管会计工作负责人于军及会计机构负责人(会计主管 人员)耿兰声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能面临的风险详见本报告"第四节 经营情况讨论与分析"之"十、 公司面临的风险和应对措施"。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 重要提示、目录和释义 2 | | --- | | 第二节 公司简介和主要财务指标 5 | | 第三节 公司业务概要 8 | | 第四节 经营情况讨论与分析 10 | | 第五节 重要事项 17 | | 第六节 股份变动及股东情况 24 | | 第七节 优先股相关情况 27 | | 第八节 董事、监事、高级管理人员情况 28 | | 第九节 公司债相关情况 30 | | 第十节 财务报告 31 | | 第十一节 备查文件目录 136 | 通化金马药业集团股份有限公司 2017 年半年度报告全文 通化金马药业集团股份有限公司 2017 ...